Lilly underlines what's at stake in Brexit talks

Plenty of senior industry figures and major companies have tried to explain the risks posed to parts of pharma’s value chain by Brexit since the UK public voted to leave the European Union (EU) in June 2016.

So far the warnings issued in the media and lobbying to government have not yet given the industry the firm guarantees they are seeking, so companies remain in the dark about what the UK’s exit deal with the EU might look like as the two sides start discussing the future relationship and transition deal.

"Our UK presence has now become Lilly’s biggest research operation outside of the USA"